- Home
- BAH vs ARWR Comparison
BAH vs ARWR Comparison
Compare BAH & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | ARWR |
|---|---|---|
| Founded | 1914 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.6B |
| IPO Year | 2010 | 1993 |
Fundamental Metrics
Financial Performance| Metric | BAH | ARWR |
|---|---|---|
| Price | $92.03 | $68.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $109.50 | $60.70 |
| AVG Volume (30 Days) | 2.2M | ★ 3.3M |
| Earning Date | 01-30-2026 | 11-25-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 3.12 | N/A |
| EPS | ★ 6.54 | N/A |
| Revenue | ★ $11,706,000,000.00 | $829,448,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $14.19 | ★ N/A |
| Revenue Growth | 2.42 | ★ 23258.15 |
| 52 Week Low | $79.23 | $9.57 |
| 52 Week High | $146.95 | $72.36 |
Technical Indicators
Market Signals| Indicator | BAH | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 72.80 |
| Support Level | $89.97 | $68.01 |
| Resistance Level | $95.34 | $72.36 |
| Average True Range (ATR) | 2.25 | 4.99 |
| MACD | 1.45 | 1.03 |
| Stochastic Oscillator | 76.11 | 86.66 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.